Micell reduces size of DES trial following positive results
This article was originally published in Clinica
Executive Summary
Micell Technologies is to shrink its planned Phase II study of its MiStent drug-eluting stent (DES) following positive data from its first-in-human trial. The move could potentially accelerate the device's route to the European market.